The Promise and Challenge of Cancer Immunotherapy
The high specificity and potent cytotoxicity of immune system effector cells make them promising agents for extirpating liquid cancers. Though the list of efficacious cell-mediated immunotherapies is growing, realizing the full therapeutic potential of this field will require: (1) continued elucidation of the mechanisms underlying cancer cell recognition and immune cell-mediated killing, and (2) an ability to screen immunotherapy constructs/conditions using patient-derived effector and/or target cells to identify optimal treatment regimens. Fundamental to both of the above is the ability to quantitatively monitor the potency of immune cell-mediated killing of target liquid cancer cells under controlled conditions in vitro. Traditional cell killing assays suffer from drawbacks that prevent them from meeting this need efficiently.
Shortcomings of Traditional Assays
Immune cell-mediated killing can be studied by measuring the activation of effector cells or their secretion of cytotoxic molecules (perforin, granzymes, etc.). While these readouts are indeed useful, they don’t necessarily correlate with target cell killing efficiency – which is the ultimate measure of therapeutic efficacy. Assays focused on the response of target cells primarily monitor the release of either previously added labels (such as 51Cr or fluorescent dyes) or endogenous biomolecules (GAPDH, LDH, etc.) upon target cell lysis. Besides the potential artifacts associated with using exogenous labels, the time frame over which such labels are useful is extremely narrow (due to the spontaneous leakage of label out of target cells). Moreover, release assays as a whole suffer from low sensitivity, low efficiency/throughput, and the fact that only endpoint data (mere snapshots in a cell response continuum) is produced.
Using xCELLigence to Monitor the Efficacy of Immunotherapies that Target Liquid Cancers
ACEA’s xCELLigence® Real-Time Cell Analysis (RTCA) instruments utilize gold microelectrodes embedded in the bottom of microtiter wells to non-invasively monitor the status of adherent cells. Parameters analyzed include cell number, cell size/shape, and cell-substrate attachment strength. Though they are not naturally adherent, liquid cancer cells can be immobilized on the plate bottom by pre-coating the wells with a tethering antibody. Upon exposure to diverse immunotherapies (NK cell, T cells, CART, oncolytic virus, checkpoint inhibitors, etc.) the target cell response is automatically recorded by the xCELLigence® instrument as shown in detail below. The major distinguishing features of this technology include enhanced sensitivity, the preclusion of labels, simple workflow and, importantly, continuous kinetic measurement of target liquid cancer cell health/behavior.
Step 1: The target liquid cancer cells are first seeded in the wells of an electronic microtiter plate (E-Plate®) that have been pre-coated with a tethering antibody. Interaction of the seeded cells with the gold microelectrodes impedes the flow of electric current between electrodes. This impedance value, plotted as a unitless parameter called “Cell Index”, increases as cells proliferate and then plateaus as cells approach 100% confluence.
Step 2: When added subsequently, non-adherent effector cells (i.e. immune cells) in suspension do not cause impedance changes in and of themselves (due to lack of adherence to the gold microelectrodes).
Step 3: If effector cells and/or antibodies induce the destruction of the target cells, this cytolytic activity can be sensitively and precisely detected. The continuous acquisition of impedance data for each well of an E-Plate enables the generation of real-time killing curves for multiple conditions simultaneously.
ACEA has developed three kits which enable the evaluation of immunotherapies that target two different types of liquid cancers:
Click here to request pricing information on our xCELLigence Immunotherapy Kits
|Kit Name||Tethering Reagent||Validated Effector Cells†||Validated Target Cells†|
|B Cell Killing (anti-CD40) Assay||anti-CD40||NK-92
primary CD8+ T cells
primary B cells
|B Cell Killing (anti-CD19) Assay||anti-CD19||NK-92
primary CD8+ T cells
primary B cells
|Leukemic Cell Killing (anti-CD29) Assay||anti-CD29||NK-92*||K562|
†The cell types listed here have already been successfully utilized. However, the kit is amenable to use with many other cell types.
*Because NK cells express low levels of CD29, they can be tethered by the anti-CD29 tethering reagent that is used in this assay. Although the impedance signal resulting from NK cells can be subtracted using the xIMT software, the kit is most effective when using alternative effector cell types such as T cells, CAR-T, etc.).